22
Participants
Start Date
February 5, 2021
Primary Completion Date
March 11, 2022
Study Completion Date
April 22, 2022
AMT-101 (oral)-Dose A
AMT-101 is an orally administered biologic therapeutic, taken once daily.
AMT-101 (oral)-Dose B
AMT-101 is an orally administered biologic therapeutic, taken once daily.
Semmelweis Egyetem I. sz Belgyogyaszati Klinika, Budapest
Chevy Chase Clinical Research, Chevy Chase
UKSH Universitätsklinikum Schleswig-Holstein, Kiel
University of North Carolina GI, Chapel Hill
CHU de Toulouse - Hôpital Rangueil, Toulouse
Vanderbilt University Medical Center, Nashville
Gastrointestinal Asssociates- GIA Clinical Trials, LLC, Knoxville
Gastro One, Germantown
Gastrointestinal Associates - Jackson, Flowood
CHU Saint Etienne - Hopital Nord, Saint-Priest-en-Jarez
Hospital Universitario y Politecnico La Fe de Valencia, Valencia
CHRU Nancy - Hopital de Brabois, Vandœuvre-lès-Nancy
Mayo Clinic, Rochester
University of Chicago Medical Center, Chicago
Tyler Research Institute, LLC, Tyler
University of Utah Health Sciences Center, Salt Lake City
Washington Gastroenterology, Tacoma, Tacoma
Connecticut Clinical Research Institute, Bristol
UZ Leuven - University Hospital Gasthuisberg, Leuven
Groupe santé CHC / Clinique du MontLégia, Liege, Liège
CHU de Rennes - Hopital de Pontchaillou, Rennes
Klinik für Innere Medizin KIM IV, Jena
University Hospital Tübingen, Tübingen
Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar, Szeged
ETZ - Elisabeth, Tilburg
Clarunis Bauchzentrum, Basel
University Hospital of Zürich, Zurich
GI Research Institute, Vancouver
Praxis fur Gastroenterologie am Bayerischen Platz, Berlin
MAC Clinical Research - Blackpool, Blackpool
MAC Clinical Research - Liverpool, Prescot
MAC Clinical Research - Cannock, Cannock
MAC Clinical Research - Leeds, Leeds
MAC Clinical Research - Manchester, Manchester
Lead Sponsor
Applied Molecular Transport
INDUSTRY